E-GLADES Drug Patent Profile
✉ Email this page to a colleague
Which patents cover E-glades, and when can generic versions of E-glades launch?
E-glades is a drug marketed by Mylan and is included in one NDA.
The generic ingredient in E-GLADES is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for E-glades
A generic version of E-GLADES was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for E-GLADES
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 6,473 |
Formulation / Manufacturing: | see details |
DailyMed Link: | E-GLADES at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for E-GLADES
US Patents and Regulatory Information for E-GLADES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan | E-GLADES | erythromycin | GEL;TOPICAL | 065009-001 | Mar 18, 2002 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |